Our intraocular device and imaging evaluation services provide a uniquely integrated approach for assessing the safety, durability, function, and biocompatibility of novel ophthalmic devices under clinically relevant conditions in NHPs. We routinely test and validate devices including intraocular lenses, glaucoma drainage implants, ocular drug-eluting reservoirs, and advanced gene therapy delivery systems, all evaluated under carefully controlled preclinical environments designed to replicate human use scenarios. Our high-resolution ophthalmic imaging suite—comprising spectral-domain and swept-source OCT, scanning laser ophthalmoscopy, adaptive optics, ultrasound biomicroscopy, and widefield fundus imaging—allows for precise, longitudinal tracking of device placement, stability, tissue interaction, and therapeutic release kinetics. Functional endpoints are further supported by electrophysiology (ERG, VEP), behavioral vision assays, and correlative histology, which together generate complete translational datasets covering both anatomical and functional outcomes. Devices are evaluated for both acute tolerability and long-term performance, with immune responses, inflammatory profiles, and tissue remodeling monitored through multiplex cytokine assays and immunohistochemistry.

 

All studies are performed by experienced surgical staff with veterinary ophthalmology oversight, ensuring subject welfare and data reliability throughout extended study timelines. With GLP compliance, robust documentation, and regulatory-ready data output, our platform enables rapid innovation cycles, mitigates developmental risk, and provides the rigorous evidence required for regulatory submissions, clinical translation, and commercial adoption of ophthalmic devices.